Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 March 2022 | Story NONSINDISO QWABE | Photo Supplied
Dr Ralph Clarke
Dr Ralph Clark, Director of the Afromontane Research Unit.

The African Mountain Research Foundation (AMRF), in association with the Afromontane Research Unit (ARU) of the University of the Free State (UFS), and the Global Mountain Safeguard Research Programme (GLOMOS), is hosting the first-ever Southern African Mountain Conference (SAMC2022). The theme of the conference is Southern African Mountains – their value and vulnerabilities.

The conference will bring relevant people together into one space for networking and information sharing, leading to more robust regional and international collaborations and comparative mountain studies with an increase in research activities, student capacity, researcher capacity and academic outputs that feed into policy and action. 

The conference will take place from 14 to 17 March 2022 in the majestic Maloti-Drakensberg Mountains in South Africa and Lesotho. 

According to the SAMC2022 website, this is a truly Southern African regional mountain conference, targeting the African region south of the Congo rainforest (DRC) and Lake Rukwa (Tanzania), but including Madagascar, the Comoros and the Mascarenes (i.e., Angola, the Comoros, the Democratic Republic of the Congo [southern mountains], Eswatini, Lesotho, Madagascar, Malawi, Mauritius, Mozambique, Namibia, La Réunion, South Africa, southern Tanzania, Zambia, and Zimbabwe).

Dr Ralph Clark, ARU Director, said the conference would be a high-level international event with UNESCO patronage and very valuable sponsors.

“The programme will have six parallel tracks (one being dedicated to postgraduate students), with about 200 papers being delivered. In addition, we have some very high-profile special sessions, such as an MRI special session on long-term monitoring activities and associated data availability for climate change-related applications across Africa’s mountains, as well as a UNESCO special session on regional collaboration. We also have Prof Julian Bayliss, described as the man who discovered an unseen world, as the guest speaker at the closing event.”

The conference will bring together relevant people in one space for networking and information sharing, leading to more robust regional and international collaborations and comparative mountain studies, with an increase in research activities, student capacity, researcher capacity, and academic outputs that feed into policy and action.

The GLOMOS team, one of the long-term partners of the ARU, spent the week of 8 to 11 March 2022 on the Qwaqwa Campus to strengthen collaboration and pave the way for new research opportunities in Phuthaditjhaba and the Maloti-Drakensberg.
GLOMOS represents an interface between the United Nations University Institute for Environment and Human Security (UNU-EHS) and Eurac Research. Postdoctoral fellow, Dr Stefano Terzi, said: “It’s very interesting for us to look at the Maloti-Drakensberg area because of its diversity. We are in the process of really exciting collaborations.”
Their projects include an understanding of the root causes of land degradation and improving decision-making processes for current water management within the context of water scarcity in the Maloti-Drakensberg.
• For more information on the speakers and the programme, click here 


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept